How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | REGNREGENERON PHARMACEUTICALS, INC. | 950220.KQ950220.KQ | AMGNAMGEN INC | GILDGILEAD SCIENCES, INC. | Median of the restexcluding REGN |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $805.67▼ 1.81 (0.22%) | ₩1647.00▼ 41.00 (2.43%) | $438.34▼ 0.60 (0.14%) | $157.19▲ 3.62 (2.36%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 8.7/10 | 2.0/10 | 8.0/10 | 9.0/10 | 8.0/10 |
| Market value | $84.27B | $11.04B | $236.18B | $195.07B | |
| Revenue | $14.34B | $94.8M | $36.75B | $29.44B | |
| Profit | $4.50B | -$31.80B | $7.71B | $8.51B | |
| Revenue growthChange in sales versus the prior year. | 1.0% | -44.3% | 10.0% | 2.4% | 2.4% |
| Gross marginShare of sales left after the direct cost of producing them. | — | 100.0% | 67.2% | 78.8% | 78.8% |
| Operating marginShare of sales left after running the business, before interest and tax. | 24.9% | -26596.5% | 24.7% | 34.0% | 24.7% |
| Profit marginProfit kept from each dollar of sales. | 31.4% | -33531.4% | 21.0% | 28.9% | 21.0% |
| Free cash flow marginCash left after capital spending, as a share of sales. | 28.4% | -34003.6% | 22.0% | 32.1% | 22.0% |
| Return on equityProfit against the owners' stake in the company. | 14.4% | -53.7% | 89.1% | 37.5% | 37.5% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | 10.2% | -71.1% | 14.4% | 21.7% | 14.4% |
| P/E ratioPrice paid per dollar of annual profit. | 18.71x | — | 30.63x | 22.92x | 26.78x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | 20.17x | — | 19.77x | 20.44x | 20.11x |
| Price to book | 2.70x | 0.19x | 27.28x | 8.59x | 8.59x |
| Debt to equityTotal liabilities compared with owners' stake. | 0.30x | 0.39x | 9.46x | 1.60x | 1.60x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 6/8 | 3/8 | 8/9 | 8/9 | 8.0 |
| Bankruptcy riskAltman Z-Score zone. | safe | distress | grey | safe |
How REGN compares with the others
- REGN's operating margin of 24.9% is in line with the median of the other companies selected (24.7%).
- Its revenue growth of 1.0% is in line with the median of the other companies selected (2.4%).
- It trades at a lower P/E than the median of the other companies selected: 18.7x against 26.8x.
- Its liabilities are lower relative to equity than the median of the other companies selected: 0.3x against 1.6x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.